通过精确识别淋巴结扩散风险较低的患者, 一项新的检测可能会避免许多黑色素瘤患者不必进行活检. A new test may spare many melanoma patients unnecessary biopsies by accurately identifying those at low risk of lymph node spread.

新的基因组测试,Merlin CP-GEP,通过分析现有肿瘤组织中的八种基因以及肿瘤年龄和厚度,可能有助于许多黑皮瘤患者避免不必要的淋巴结活性细胞。 A new genomic test, Merlin CP-GEP, may help many melanoma patients avoid unnecessary lymph node biopsies by analyzing eight genes in existing tumor tissue along with age and tumor thickness. 美国对1 761名病人进行了大规模试验,发现测试准确识别了低风险个人,93%的人淋巴结中没有癌症。 A large U.S. trial of 1,761 patients found the test accurately identified low-risk individuals, with 93% having no cancer in their lymph nodes. 大约25%的高危病人已经传播,这表明测试可以指导个性化治疗。 About 25% of high-risk patients did have spread, suggesting the test can guide personalized treatment. 目前,大多数活性细胞显示没有癌症,而该手术也带来风险。 Currently, most biopsies show no cancer, and the procedure carries risks. 该试验使用已经收集的组织,在进一步验证之前,可以减少过度治疗,改善护理。 The test, which uses tissue already collected, could reduce overtreatment and improve care, pending further validation.